In connection with the start of the phase 3 trials of PCV21, Sanofi has expanded its alliance with South Korea-based SK Bio, ...

Sanofi and SK bioscience have entered into a new chapter of their collaboration in pneumococcal vaccines with an expanded agreement to develop, license and commercialize next-generation PCVs for both ...

SK bioscience and Sanofi have expanded their agreement to jointly develop pneumococcal conjugate vaccines (PCVs) targeting ...

Healthcare professionals in the U.S. have noticed a significant increase in vaccine hesitancy among their patients, according ...

A fatal disease that can strike down babies and little children has soared to a 20-year high in Australia, a leading health ...

Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in ...

The Immunisation Foundation of Australia (IFA) warned there could be a deadly jump in cases in 2025 if new vaccines targeting more deadly strains of pneumococcal failed to be fast-tracked by the ...

SK Bioscience, Sanofi collaborate on next-gen pneumococcal vaccine development SK Bioscience and Sanofi join forces to ...

Pfizer is fending off investors’ fears about threats to its vaccine business under the Trump administration.

Conner: Tell us about the new recommendations for the pneumonia vaccine.

Opens in a new tab or window Share on X ... According to the investigators of a newly published study on the waning of pneumococcal vaccines responses in people with inflammatory arthritis ...

French pharma major Sanofi says it has entered into a new chapter of the collaboration with South Korean firm SK bioscience ...